Treatment with SHP2 inhibitor JAB-3312 shows body weight changes in KRASG12C mutant xenograft models, suggesting enhanced responses to combined therapies.
Supplementary Figure S3. Body weight change of KRASG12C mutant tumors. A-E. Body weight change of SW837 (A), MIA PaCa-2 (B), CR6243 (C), CR6256 (D), and LU6405 (E) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean ± SEM was shown.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: